Diosmin showed its anti‐carcinogenic activity in many types of cancer, where it displays anti‐tumor activity through multiple signaling pathways and inhibition, including PI3K‐Akt, NF‐κB, and VEGF (Helmy et al., 2020); in the case of colorectal cancer, the combination of diosmin and dactolisib suppresses cancer cell proliferation and induces apoptosis by downregulating PI3K/AKT/mTOR/NF‐κB signaling (Helmy et al., 2020). This evidence concerns the gene AKT1 and neoplasm.